Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 196

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 5
Chunk 196
---
   ​           ​   ​               ​   ​       10,604    ​   ​         9,482
Gilead royalties on Jyseleca                                      ​   ​           ​   Ö               ​   ​       10,604    ​   ​         9,466
Other royalties                                                   ​   ​           ​   Ö               ​   ​       —         ​   ​            16
​                                                                 ​   ​           ​   ​               ​   ​       ​         ​   ​             ​
Total collaboration revenues                                      ​   ​           ​   ​               ​   €       240,786   ​   €       239,724
​
​
We recognize the consideration from Gilead allocated to the drug discovery platform on a linear basis over the 10-year period of our collaboration, of which we recognized €230.2 million in revenue in 2024. 
Since signing of the letter of intent with Alfasigma in October 2023, we classified all activities that were directly related to the Jyseleca® business, including the revenue recognition related to the filgotinib performance obligation, as discontinued operations in accordance with IFRS 5. We refer to note 5 “Discontinued Operations” in our consolidated financial statements appended to this annual report for additional information.
For the year ended December 31, 2024 we also recognized in revenue €10.6 million of royalties from Gilead on filgotinib. The royalties on sales of Jyseleca® performed by Gilead in Japan were not reported as discontinued operations as we still have the right to receive those royalties on future sales made by Gilead and its commercialization partners (this right is not subject to transfer to Alfasigma as part of the transfer of the Jyseleca® business to them).
The outstanding balance of deferred income from the Gilead collaboration for the drug discovery platform at December 31, 2024 amounted to €1,069.0 million.
Cost of sales
Cost of sales related to the supply of Jyseleca® to Alfasigma under the transition agreement. The related revenues are reported in total net revenues, as supply revenues.
R&D expenses
The following table summarizes our R&D expenses for the years ended December 31, 2024 and 2023, together with the changes to those items.

                     ​                        ​    ​         ​         ​       ​         ​       ​   ​